Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Gain Therapeutics (Group)

Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3B Future Health Fund (previously known as Helsinn Investment Fund) and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA., a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc. *

 

Period Start 2017-12-31 established (s-off)
  Predecessor Minoryx Therapeutics S.L.
Product Industry SEE-Tx platform (Site-directed Enzyme Enhancement Therapy platform
Persons Person Leoni, Lorenzo (TiVenture Fund 201802 Managing Director + Gain Therapeutics 201802– interim CEO before Telormedix)
  Person 2 Barril, Xavier (Gain Therapeutics 201802 CSO before Minoryx Therapeutics + Vernalis)
     
Region Region Lugano TI
  Country Switzerland
  Street 6 Via Francesco Soave
  City 6900 Lugano TI
  Tel +41-91-921-1131
    Address record changed: 2024-01-05
     
Basic data Employees B: 11 to 50 (2021-12-31)
  Currency USD
  Annual sales 164,994 (revenues, total, consolidated (2021) 2021-12-31)
  Profit -13,890,606 (2021-12-31)
  Cash 36,880,673 (2031-12-31)
     
    * Document for »About Section«: Gain Therapeutics, Inc.. (9/10/20). "Press Release: Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program". Bethesda, MD.
     
   
Record changed: 2023-07-10

Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for Gain Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px




» top